Actively Recruiting
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Led by Programme National de Lutte contre l'Onchocercose, Republic of the Congo · Updated on 2024-09-20
99
Participants Needed
2
Research Sites
84 weeks
Total Duration
On this page
Sponsors
P
Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Lead Sponsor
I
Institut de Recherche pour le Developpement
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
CONDITIONS
Official Title
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent
- Men or women aged 18 to 65 years inclusive
- Carrier of Loa loa microfilaremia
- Body weight at least 40 kg for women and 45 kg for men, and less than 90 kg
- In good health based on medical questionnaire and clinical exam
- No acute or chronic infections
You will not qualify if you...
- Participated in any study other than observational within 4 weeks before this study
- Received any vaccination within 4 weeks before this study
- Had infection requiring treatment in the 10 days before this study
- Treated with clozapine, phenothiazines, sulfasalazine, carbamazepine, synthetic antithyroid drugs, ticlopidine, cimetidine, or gold salts within 10 days before treatment
- Known immunosuppressive condition
- Past or present neurological or neuropsychiatric disease including epilepsy
- History of agranulocytosis
- Used cocaine or other drugs of abuse in 72 hours before treatment
- Any condition posing undue risk as judged by investigator
- Known intolerance to levamisole
- Donated more than 500 mL blood in the 8 weeks before study entry
- Symptoms or lab signs of systemic disorders affecting kidney, liver, heart, lungs, skin, immune system, psychiatric status, or other
- Taken ivermectin or levamisole in last 6 months; mebendazole or albendazole in last month
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Supervisor
Sibiti, Komono, Republic of the Congo
Actively Recruiting
2
General Supervisor
Sibiti, Mokassi, Republic of the Congo
Actively Recruiting
Research Team
J
Jéremy CAMPILLO, PharmD PhD
CONTACT
B
Bachiratou SAHM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here